Cargando…

Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality

SIMPLE SUMMARY: PARP inhibitors (PARPi) have been administered to treat BRCA1/2-mutated/deficient malignancies. Nevertheless, the resistance to PARPi is emerging in experimental and clinical interventions. Importantly, the resistance originated from diverse mechanisms, therefore requiring tremendous...

Descripción completa

Detalles Bibliográficos
Autores principales:	Le, Bac Viet, Podszywałow-Bartnicka, Paulina, Piwocka, Katarzyna, Skorski, Tomasz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741207/ https://www.ncbi.nlm.nih.gov/pubmed/36497275 http://dx.doi.org/10.3390/cancers14235795

Ejemplares similares

Increased phosphorylation of eIF2α in chronic myeloid leukemia cells stimulates secretion of matrix modifying enzymes
por: Podszywalow-Bartnicka, Paulina, et al.
Publicado: (2016)

Stimulators of Mineralization Limit the Invasive Phenotype of Human Osteosarcoma Cells by a Mechanism Involving Impaired Invadopodia Formation
por: Cmoch, Anna, et al.
Publicado: (2014)

TIAR and FMRP shape pro-survival nascent proteome of leukemia cells in the bone marrow microenvironment
por: Wolczyk, Magdalena, et al.
Publicado: (2023)

PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas
por: Czyż, Małgorzata, et al.
Publicado: (2016)

The PERK-eIF2α phosphorylation arm is a pro-survival pathway of BCR-ABL signaling and confers resistance to imatinib treatment in chronic myeloid leukemia cells
por: Kusio-Kobialka, Monika, et al.
Publicado: (2012)

Synthetic Lethality Targeting Polθ
por: Drzewiecka, Małgorzata, et al.
Publicado: (2022)

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
por: Mendes-Pereira, Ana M, et al.
Publicado: (2009)

Evolution of Pre-Existing versus Acquired Resistance to Platinum Drugs and PARP Inhibitors in BRCA-Associated Cancers
por: Yamamoto, Kimiyo N., et al.
Publicado: (2014)

Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine
por: Murata, Stephen, et al.
Publicado: (2016)

Wnt signaling inhibition confers induced synthetic lethality to PARP inhibitors
por: Angers, Stephane
Publicado: (2021)

Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
por: Zatreanu, Diana, et al.
Publicado: (2021)

Oxidized mC modulates synthetic lethality to PARP inhibitors for the treatment of leukemia
por: Brabson, John P., et al.
Publicado: (2023)

RAD52 as a Potential Target for Synthetic Lethality-Based Anticancer Therapies
por: Toma, Monika, et al.
Publicado: (2019)

Synthetic Lethality of Cohesins with PARPs and Replication Fork Mediators
por: McLellan, Jessica L., et al.
Publicado: (2012)

Enhancing synthetic lethality of PARP-inhibitor and cisplatin in BRCA-proficient tumour cells with hyperthermia
por: Oei, Arlene L., et al.
Publicado: (2017)

The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality
por: Turinetto, Margherita, et al.
Publicado: (2021)

Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells
por: Sullivan-Reed, Katherine, et al.
Publicado: (2018)

NFAT1 and NFAT3 Cooperate with HDAC4 during Regulation of Alternative Splicing of PMCA Isoforms in PC12 Cells
por: Kosiorek, Michalina, et al.
Publicado: (2014)

Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition
por: Srinivasan, Gayathri, et al.
Publicado: (2017)

Tousled-like kinases stabilize replication forks and show synthetic lethality with checkpoint and PARP inhibitors
por: Lee, Sung-Bau, et al.
Publicado: (2018)

The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment
por: Li, Shuangying, et al.
Publicado: (2022)

In Silico Screening Identifies a Novel Potential PARP1 Inhibitor Targeting Synthetic Lethality in Cancer Treatment
por: Li, Jian, et al.
Publicado: (2016)

Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival
por: Xie, Tao, et al.
Publicado: (2022)

DNA2 Nuclease Inhibition Confers Synthetic Lethality in Cancers with Mutant p53 and Synergizes with PARP Inhibitors
por: Folly-Kossi, Helena, et al.
Publicado: (2023)

Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells
por: Bajrami, Ilirjana, et al.
Publicado: (2012)

Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer
por: Asim, Mohammad, et al.
Publicado: (2017)

Combinatorial targeting of Hippo-STRIPAK and PARP elicits synthetic lethality in gastrointestinal cancers
por: An, Liwei, et al.
Publicado: (2022)

Co-targeting WIP1 and PARP induces synthetic lethality in hepatocellular carcinoma
por: Chen, Miaoqin, et al.
Publicado: (2022)

PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction In Vitro and In Vivo
por: Fröhlich, Lisa Marie, et al.
Publicado: (2023)

XRN2 interactome reveals its synthetic lethal relationship with PARP1 inhibition
por: Patidar, Praveen L., et al.
Publicado: (2020)

Synthetic lethality between VPS4A and VPS4B triggers an inflammatory response in colorectal cancer
por: Szymańska, Ewelina, et al.
Publicado: (2020)

OGG1 Inhibition Triggers Synthetic Lethality and Enhances The Effect of PARP Inhibitor Olaparib in BRCA1-Deficient TNBC Cells
por: Baquero, Juan Miguel, et al.
Publicado: (2022)

TRABID overexpression enables synthetic lethality to PARP inhibitor via prolonging 53BP1 retention at double-strand breaks
por: Ma, Jian, et al.
Publicado: (2023)

Synthetic lethal genetic interactions between Rad54 and PARP-1 in mouse development and oncogenesis
por: Tanori, Mirella, et al.
Publicado: (2016)

Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence
por: Fleury, Hubert, et al.
Publicado: (2019)

Targeting SMYD3 to Sensitize Homologous Recombination-Proficient Tumors to PARP-Mediated Synthetic Lethality
por: Sanese, Paola, et al.
Publicado: (2020)

Histone Deacetylases (HDAC) Inhibitor—Valproic Acid Sensitizes Human Melanoma Cells to Dacarbazine and PARP Inhibitor
por: Drzewiecka, Małgorzata, et al.
Publicado: (2023)

Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
por: Lappin, Katrina M., et al.
Publicado: (2022)

A potential synthetic lethal strategy with PARP inhibitors: perspective on ‘Inactivation of the tumor suppressor p53 by long noncoding RNA RMRP’
por: Hao, Qian, et al.
Publicado: (2021)

New Synthetic Lethality Re-Sensitizing Platinum-Refractory Cancer Cells to Cisplatin In Vitro: The Rationale to Co-Use PARP and ATM Inhibitors
por: Folk, Watson P., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fe36quu19b4omeufc0u6ntkjrm